Editas Medicine, Inc. (EDIT) stock
EDITNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 3/3038% above fair value
$2.17+0.03 (+1.40%)
Close on Nov 13, 2026Market cap $333.27MP/E –Yield –
Editas Medicine revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Editas Medicine's revenue for the twelve months ending Sep 30, 2026 was $49.83M, up 7.4% year over year. For fiscal 2025 it was $40.52M, up 25.4% from the year before. The highest annual figure on record is $90.73M in fiscal 2020.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $40.52M | +25.4% |
| FY2024 | Dec 31, 2024 | $32.31M | -58.6% |
| FY2023 | Dec 31, 2023 | $78.12M | +296.3% |
| FY2022 | Dec 31, 2022 | $19.71M | -22.8% |
| FY2021 | Dec 31, 2021 | $25.54M | -71.8% |
| FY2020 | Dec 31, 2020 | $90.73M | +341.9% |
| FY2019 | Dec 31, 2019 | $20.53M | -35.7% |
| FY2018 | Dec 31, 2018 | $31.94M | +132.6% |
| FY2017 | Dec 31, 2017 | $13.73M | +126.8% |
| FY2016 | Dec 31, 2016 | $6.05M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $10.37M | +37.4% |
| Q2 FY2026 | Jun 30, 2026 | $11.89M | +232.3% |
| Q1 FY2026 | Mar 31, 2026 | $2.83M | -39.2% |
| Q4 FY2025 | Dec 31, 2025 | $24.74M | -19.2% |
| Q3 FY2025 | Sep 30, 2025 | $7.54M | +12265.6% |
| Q2 FY2025 | Jun 30, 2025 | $3.58M | +597.5% |
| Q1 FY2025 | Mar 31, 2025 | $4.66M | +310.4% |
| Q4 FY2024 | Dec 31, 2024 | $30.60M | -49.0% |
| Q3 FY2024 | Sep 30, 2024 | $61.00K | -98.9% |
| Q2 FY2024 | Jun 30, 2024 | $513.00K | -82.2% |
| Q1 FY2024 | Mar 31, 2024 | $1.14M | -88.5% |
| Q4 FY2023 | Dec 31, 2023 | $60.05M | +818.7% |
| Q3 FY2023 | Sep 30, 2023 | $5.34M | +12604.8% |
| Q2 FY2023 | Jun 30, 2023 | $2.89M | -54.6% |
| Q1 FY2023 | Mar 31, 2023 | $9.85M | +45.5% |
| Q4 FY2022 | Dec 31, 2022 | $6.54M | -47.6% |
| Q3 FY2022 | Sep 30, 2022 | $42.00K | -99.3% |
| Q2 FY2022 | Jun 30, 2022 | $6.36M | +1578.6% |
| Q1 FY2022 | Mar 31, 2022 | $6.77M | +4.2% |
| Q4 FY2021 | Dec 31, 2021 | $12.47M | +9.2% |
| Q3 FY2021 | Sep 30, 2021 | $6.20M | -90.1% |
| Q2 FY2021 | Jun 30, 2021 | $379.00K | -96.5% |
| Q1 FY2021 | Mar 31, 2021 | $6.50M | +13.6% |
| Q4 FY2020 | Dec 31, 2020 | $11.42M | -7.0% |
| Q3 FY2020 | Sep 30, 2020 | $62.84M | +1533.1% |
| Q2 FY2020 | Jun 30, 2020 | $10.75M | +361.3% |
| Q1 FY2020 | Mar 31, 2020 | $5.72M | +176.6% |
| Q4 FY2019 | Dec 31, 2019 | $12.28M | +100.8% |
| Q3 FY2019 | Sep 30, 2019 | $3.85M | -73.5% |
| Q2 FY2019 | Jun 30, 2019 | $2.33M | -68.4% |
| Q1 FY2019 | Mar 31, 2019 | $2.07M | -47.3% |
| Q4 FY2018 | Dec 31, 2018 | $6.12M | +66.9% |
| Q3 FY2018 | Sep 30, 2018 | $14.52M | +131.1% |
| Q2 FY2018 | Jun 30, 2018 | $7.37M | +138.0% |
| Q1 FY2018 | Mar 31, 2018 | $3.93M | +475.8% |
| Q4 FY2017 | Dec 31, 2017 | $3.67M | – |
| Q3 FY2017 | Sep 30, 2017 | $6.28M | – |
| Q2 FY2017 | Jun 30, 2017 | $3.10M | – |
| Q1 FY2017 | Mar 31, 2017 | $682.00K | – |
See a number that looks wrong?